Results 131 to 140 of about 151,900 (300)
, 2012 Jonathan Montomoli,1 Stephen Jacques Hamilton-Dutoit,2 Trine Frøslev,1 Aliki Taylor,3 Rune Erichsen11Department of Clinical Epidemiology, Aarhus University Hospital, Aarhus, Denmark; 2Institute of Pathology, Aarhus University Hospital, Aarhus,
Montomoli J +4 more
core
Animal Models and Experimental Medicine, EarlyView.Using F1 (C57BL/6J/Smad4+/− X CC) mice, we found that partial loss of Smad4 promotes liver carcinogenesis in a strain‐dependent manner, highlighting the importance of genetic modifiers in tumor susceptibility. The use of Collaborative Cross mice provides a valuable platform for uncovering genotype‐specific cancer susceptibilities in preclinical ...
Osayd Zohud +3 more
wiley +1 more source
Self-contained velocity feedback unit with a seismic flywheel electromagnetic actuator
, 2023 ALEKSANDER KRAS, PAOLO GARDONIO
core +1 more source
Annals of Neurology, EarlyView.Objective As leptomeningeal metastasis (LM) has a poor prognosis, reliable cerebrospinal fluid (CSF) diagnostic biomarkers are urgently needed. This study evaluated the diagnostic value of CSF growth differentiation factor 15 (GDF15) in LM from lung adenocarcinoma (LUAD) and breast cancer (BC).
Haoyu Ruan +12 more
wiley +1 more source
Polskie rozwiązania w zakresie rezerw obowiązkowych banków
Seminare, 2004 Ireneusz Kraś
doaj +1 more source
Targeting Macropinocytosis in Oncogenic KRAS Mutant Pancreatic Cancer Cells
KRAS is a frequently mutated oncogene that regulates cell division and promotes pancreatic cancer development. Mutations in KRAS increase resistance to chemotherapy and drive cancer cell transformation.
Kionga, Teresa Bochaberi
core
Distinct Molecular Pathways Supporting Sjögren Disease Clusters and Disease Progression
Arthritis &Rheumatology, EarlyView.Objective Sjögren disease (SjD) is a heterogeneous autoimmune disease. We aimed to investigate blood transcriptomic signatures and disease progression among three recently defined clusters of patients with SjD: (1) B cell active disease with low symptom burden (BALS), (2) high systemic activity (HSA), and (3) low systemic activity with high symptom ...
Sacha E. Silva‐Saffar +6 more
wiley +1 more source
Personalized treatment for advanced colorectal cancer: KRAS and beyond
, 2013 Gargi Surendra Patel,1 Christos S Karapetis,1,2 1Department of Medical Oncology, Flinders Medical Centre, 2Flinders Centre for Innovation in Cancer, Flinders University, Bedford Park, Adelaide, SA, Australia Abstract: Targeted therapies have improved the
Karapetis CS, Patel GS
core
British Journal of Clinical Pharmacology, EarlyView.Aims Predetermined treatment duration limits (PTDLs) are often used by Taiwan's National Health Insurance Administration to contain healthcare costs, but they may compromise patient outcomes. Therefore, we studied Taiwan's 2017 extension of the bevacizumab PTDL from 24 to 36 weeks in metastatic colorectal cancer (mCRC) to evaluate whether prolonged ...
Wei‐Ming Huang +6 more
wiley +1 more source
Molecular landscape of borderline ovarian tumours: A systematic review
Open MedicineBorderline ovarian tumours (BOTs) show intriguing characteristics distinguishing them from other ovarian tumours. The aim of the systematic review was to analyse the spectrum of molecular changes found in BOTs and discuss their significance in the ...
Sadlecki Pawel +1 more
doaj +1 more source